TY  - CONF
AU  - Bathe, Tim
AU  - Salomasova, Svetlana
AU  - Lalia, Manvir
AU  - Kunze, Lea
AU  - Palumbo, Giovanna
AU  - Oos, Rosel
AU  - Joseph, Emanuel
AU  - Brendel, Matthias
TI  - Multi‐tracer PET monitoring of an immunomodulatory therapy in 4R tauopathy: Evaluating a novel drug's impact on glial function and protein pathology
JO  - Alzheimer's and dementia
VL  - 21
IS  - S2
SN  - 1552-5260
M1  - DZNE-2026-00041
SP  - e104796
PY  - 2025
AB  - The prevalence of neurodegenerative diseases (ND), including Alzheimer's disease (AD) and non-AD tauopathies, is projected to rise significantly by 2050 due to an aging global population. Chronic neuroinflammation, driven by glial activation in response to protein pathologies, is a major contributor to disease progression. Targeting glial dysfunction through immunomodulatory therapies offers a promising approach to mitigate the effects of tauopathies and other ND.PS19 mice receive chronic treatment with GV1001 over 5 months. Serial neuroimaging techniques, including PET scans targeting tau protein, microglial activation, and astrocytic responses, are employed to assess treatment effects in vivo (Figure 1). Postmortem validation is performed using immunohistochemistry and biochemical methods, comparing treated mice to placebo and non-transgenic controls.The research scope is to monitor the efficacy of GV1001 in a transgenic tau mouse model (PS19) with an early-intervention biomarker study using molecular biology and neuroimaging techniques including TSPO (microglia) PET, deprenyl (astroglia) PET, tau PET (perfusion and retention) and CSF markers of inflammation (e.g. sTREM2) and neurodegeneration (NfL). Preliminary findings, expected to be presented at the conference, will provide insights into the drug's ability to modulate glial activity, restore homeostasis, and reduce tau pathology.This study highlights the potential of monitoring immunomodulatory strategies to address the complex interplay between chronic neuroinflammation and protein aggregation in ND. If successful, these findings could inform the development of novel therapeutic approaches for AD and related disorders, bridging the gap between preclinical research and clinical application.
T2  - Alzheimer’s Association International Conference
CY  - 27 Jul 2025 - 31 Jul 2025, Toronto (Canada)
Y2  - 27 Jul 2025 - 31 Jul 2025
M2  - Toronto, Canada
KW  - Animals
KW  - Biomarkers: cerebrospinal fluid
KW  - Biomarkers: metabolism
KW  - Mice
KW  - Mice, Transgenic
KW  - Disease Models, Animal
KW  - Alzheimer Disease: drug therapy
KW  - Positron-Emission Tomography
KW  - tau Proteins: metabolism
KW  - Humans
KW  - Brain: metabolism
KW  - Brain: pathology
KW  - Brain: diagnostic imaging
KW  - Brain: drug effects
KW  - Tauopathies: drug therapy
KW  - Microglia: metabolism
KW  - Biomarkers (NLM Chemicals)
KW  - tau Proteins (NLM Chemicals)
LB  - PUB:(DE-HGF)1 ; PUB:(DE-HGF)16
DO  - DOI:10.1002/alz70856_104796
UR  - https://pub.dzne.de/record/283145
ER  -